A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets.

cancer myeloid-derived suppressor cells tumor-infiltrating macrophages

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
11 Jun 2021
Historique:
received: 05 05 2021
revised: 27 05 2021
accepted: 09 06 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 3 7 2021
Statut: epublish

Résumé

Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to conventional myeloid cells, their identification and purification from within the tumors is technically difficult and makes their study a challenge. We differentiated myeloid cells modeling the three main tumor-infiltrating types together with uncommitted macrophages, using ex vivo differentiation methods resembling the tumor microenvironment. The phenotype and proteome of these cells was compared to identify linage-dependent relationships and cancer-specific interactome expression modules. The relationships between monocytic MDSCs and TAMs, monocytic MDSCs and granulocytic MDSCs, and hierarchical relationships of expression networks and transcription factors due to lineage and cancer polarization were mapped. Highly purified immunosuppressive myeloid cell populations that model tumor-infiltrating counterparts were systematically analyzed by quantitative proteomics. Full functional interactome maps have been generated to characterize at high resolution the relationships between the three main myeloid tumor-infiltrating cell types. Our data highlights the biological processes related to each cell type, and uncover novel shared and differential molecular targets. Moreover, the high numbers and fidelity of ex vivo-generated subsets to their natural tumor-shaped counterparts enable their use for validation of new treatments in high-throughput experiments.

Identifiants

pubmed: 34208043
pii: jpm11060542
doi: 10.3390/jpm11060542
pmc: PMC8230595
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fundación Científica Asociación Española Contra el Cáncer
ID : PROYE16001ESCO
Organisme : Instituto de Salud Carlos III
ID : FIS PI17/02119
Organisme : Instituto de Salud Carlos III
ID : PI20/00010
Organisme : Instituto de Salud Carlos III
ID : COV20/00000
Organisme : Instituto de Salud Carlos III
ID : TRANSPOCART ICI19/00069
Organisme : Departamento de Salud, Gobierno de Navarra
ID : BMED 050-2019
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : AGATA, Ref 0011-1411-2020-000013
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : LINTERNA, Ref. 0011-1411-2020-000033
Organisme : Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra
ID : DESCARTHES, 0011-1411-2019-000058
Organisme : Horizon 2020 Framework Programme
ID : ISOLDA; ID: 848166

Références

Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
Int J Hematol. 2015 Apr;101(4):330-41
pubmed: 25753223
Eur J Cancer. 2006 Apr;42(6):717-27
pubmed: 16520032
Proteomics. 2016 Jan;16(2):367-78
pubmed: 26403437
J Exp Med. 2008 Sep 29;205(10):2235-49
pubmed: 18809714
Cancers (Basel). 2019 Jun 11;11(6):
pubmed: 31212684
J Proteomics. 2012 Oct 22;75(18):5749-61
pubmed: 22906719
Oncotarget. 2014 Nov 30;5(22):11345-53
pubmed: 25294811
Mol Cell. 2007 Apr 13;26(1):63-74
pubmed: 17434127
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Immunity. 2016 Feb 16;44(2):303-15
pubmed: 26885857
Oncotarget. 2015 May 20;6(14):12369-82
pubmed: 25869209
Mol Cancer. 2014 Mar 02;13:43
pubmed: 24580730
J Proteome Res. 2018 Mar 2;17(3):1172-1182
pubmed: 29338241
J Exp Med. 2021 Apr 5;218(4):
pubmed: 33566112
EMBO Mol Med. 2011 Oct;3(10):581-92
pubmed: 21739608
J Immunol. 2008 Oct 1;181(7):4666-75
pubmed: 18802069
Biochem Biophys Res Commun. 2008 Mar 14;367(3):693-9
pubmed: 18166152
Curr Opin Immunol. 2018 Apr;51:76-82
pubmed: 29547768
Stem Cells. 2014 May;32(5):1149-60
pubmed: 24302476
Oncotarget. 2014 Sep 15;5(17):7843-57
pubmed: 25151659
J Leukoc Biol. 2017 Aug;102(2):325-334
pubmed: 28223316
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123
pubmed: 29032490
Blood. 2013 Mar 7;121(10):1760-8
pubmed: 23299310
Oncoimmunology. 2014 Jul 03;3(7):e945378
pubmed: 25954597
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):E2801-E2810
pubmed: 29507229
Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9053-8
pubmed: 22611194
Neoplasia. 2018 Aug;20(8):848-856
pubmed: 30025228
Nat Immunol. 2014 Sep;15(9):846-55
pubmed: 25086775
J Immunol. 2010 Apr 1;184(7):3514-25
pubmed: 20208008
Blood. 2008 Mar 15;111(6):3050-61
pubmed: 18180378
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
Arthritis Rheum. 2011 Jan;63(1):84-95
pubmed: 20967853
J Exp Med. 2011 Apr 11;208(4):643-51
pubmed: 21402738
Mol Cancer Res. 2020 Jan;18(1):166-178
pubmed: 31619507
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Invest Dermatol. 2012 Nov;132(11):2642-51
pubmed: 22718118
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
J Nanobiotechnology. 2021 Apr 13;19(1):102
pubmed: 33849551
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Cell Host Microbe. 2020 Jan 8;27(1):3-5
pubmed: 31951822
Oncotarget. 2015 Sep 29;6(29):27160-75
pubmed: 26320174
Transl Res. 2018 Jan;191:15-28
pubmed: 29106912
Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4924-E4933
pubmed: 28584133
Cell Rep. 2017 Aug 22;20(8):1818-1829
pubmed: 28834746
Genes Dev. 2020 Feb 1;34(3-4):149-165
pubmed: 31919189
Sci Rep. 2017 Aug 22;7(1):9115
pubmed: 28831118

Auteurs

Ester Blanco (E)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Maria Ibañez-Vea (M)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Genetics, Genomics and Microbiology Research Group, Institute for Multidisciplinary Research in Applied Biology (IMAB-UPNA), University Public of Navarre, Campus Arrosadía, 31006 Pamplona, Spain.

Carlos Hernandez (C)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Lylia Drici (L)

The Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.

Xabier Martínez de Morentin (X)

Bioinformatics Group, Navarrabiomed Biomedical Research Center, Institute of Health Carlos III (ISCIII), Navarra Institute for Health Research (IdiSNA), Irunlarrea 3, 31008 Pamplona, Spain.

Maria Gato (M)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Karina Ausin (K)

Proteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.

Ana Bocanegra (A)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Miren Zuazo (M)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Luisa Chocarro (L)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Hugo Arasanz (H)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Gonzalo Fernandez-Hinojal (G)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Joaquin Fernandez-Irigoyen (J)

Proteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.

Cristian Smerdou (C)

Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain.

Maider Garnica (M)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Miriam Echaide (M)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Leticia Fernandez (L)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Pilar Morente (P)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Pablo Ramos-Castellanos (P)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Diana Llopiz (D)

Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), 31008 Pamplona, Spain.
IdiSNA, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain.

Enrique Santamaria (E)

Proteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.

Martin R Larsen (MR)

Department of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.

David Escors (D)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Grazyna Kochan (G)

Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Classifications MeSH